EXELIXIS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.59 USD | -2.53% |
|
-1.53% | -10.00% |
| May. 01 | RBC Trims Exelixis' Price Target to $27 From $28, Outperform Rating Kept | MT |
| Apr. 30 | Exelixis Q1 Non-GAAP Earnings, Revenue Rise; 2024 Revenue Guidance Maintained -- Shares Fall After Hours | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 1.88B | Sales 2025 * | 2.06B | Capitalization | 6.29B |
|---|---|---|---|---|---|
| Net income 2024 * | 346M | Net income 2025 * | 449M | EV / Sales 2024 * | 2.75 x |
| Net cash position 2024 * | 1.12B | Net cash position 2025 * | 1.67B | EV / Sales 2025 * | 2.24 x |
| P/E ratio 2024 * |
19.1
x | P/E ratio 2025 * |
14.8
x | Employees | 1,310 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.74% |
More Fundamentals
* Assessed data
More news
Latest transcript on Exelixis, Inc.
More recommendations
More press releases
More news
| 1 day | -2.53% | ||
| 1 week | -1.53% | ||
| Current month | -7.97% | ||
| 1 month | -7.54% | ||
| 3 months | +7.04% | ||
| 6 months | +4.10% | ||
| Current year | -10.00% |
1 week
21.57
22.47
1 month
20.6923.89
Current year
19.2024.34
1 year
18.5224.34
3 years
14.8725.77
5 years
13.6727.80
10 years
1.2632.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 00-01-31 | |
| Director of Finance/CFO | 56 | 15-07-14 | |
Amy Peterson
CTO | Chief Tech/Sci/R&D Officer | 57 | 23-08-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alan Garber
BRD | Director/Board Member | 68 | 04-12-31 |
| Director/Board Member | 68 | 04-01-31 | |
George Poste
BRD | Director/Board Member | 79 | 04-07-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.24% | 0 M€ | +12.09% | - | |
| 2.62% | 0 M€ | -2.17% | - | |
| 1.67% | 0 M€ | -.--% | ||
| 1.59% | 0 M€ | +8.89% | ||
| 1.30% | 4 M€ | +20.15% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 21.59 | -2.53% | 2,209,905 |
| 24-05-07 | 22.15 | +1.14% | 2,595,680 |
| 24-05-06 | 21.9 | 0.00% | 2,158,487 |
| 24-05-03 | 21.9 | -0.99% | 2,475,481 |
| 24-05-02 | 22.12 | +0.89% | 3,207,625 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotes
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
Calendar
2024-05-14
- Citizens JMP Life Sciences Conference
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
21.59
USD
Average target price
26.76
USD
Spread / Average Target
+23.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.00% | 6.29B | |
| +2.93% | 108B | |
| -2.68% | 23.46B | |
| -14.60% | 21.72B | |
| -7.05% | 18.64B | |
| -38.55% | 17.45B | |
| -8.83% | 17.19B | |
| +5.51% | 13.99B | |
| +37.49% | 12.53B | |
| +329.39% | 8.81B |
- Stock Market
- Equities
- EXEL Stock